

FOI REF: 24/133

16th March 2024

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

1) How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

| | | |
|---|--|-----------|
| • | Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) | 0 |
| • | Abemaciclib + Fulvestrant | 5 |
| • | Alpelisib + Fulvestrant | 2 |
| • | Anthracycline (e.g. doxorubicin or epirubicin) as a single agent | 0 |
| • | Atezolizumab +Nab-paclitaxel/Paclitaxel | 2 |
| • | Capecitabine as a single agent | 28 |
| • | Eribulin as a single agent or in combination | 4 |
| • | Everolimus + Exemestane | 0 |
| • | Fulvestrant as a single agent | 0 |
| • | Lapatinib | 0 |
| • | Neratinib | 0 |
| • | Parp Inhibitors (Olaparib/Talazoparib) | 0 |
| • | Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) | 0 |
| • | Palbociclib + Fulvestrant | 5 |
| • | Pembrolizumab | 4 |
| • | Platinum (e.g. carboplatin or cisplatin) as a single agent | 4 |
| • | Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) | 0 |
| • | Ribociclib + Fulvestrant | 19 |
| • | Sacituzumab Govitecan | 2 |
| • | Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent | 62 |
| • | Taxane and/or Anthracycline in combination | 0 |

| | | |
|---|--|-----------|
| • | Trastuzumab as a single agent or in combination | 38 |
| • | Trastuzumab emtansine | 11 |
| • | Transtuzumab deruxtecan | 2 |
| • | Any other active systemic anti-cancer therapy | |
| | Abemaciclib | 19 |
| | Denosumab | 87 |
| | Everolimus | 2 |
| | Epirubicin Cyclophosphamide | 30 |
| | Epirubicin Cyclophosphamide + pembrolizumab | 4 |
| | Paclitaxel/Carboplatin | 2 |
| | Paclitaxel/Carboplatin pembrolizumab | 16 |
| | Palbociclib | 18 |
| | Palbociclib + Denosumab | 15 |
| | Phesgo | 30 |
| | Phesgo + docetaxel | 4 |
| | TCHP + Phesgo | 13 |
| | Ribociclib | 39 |

2) Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

East Sussex Healthcare NHS Trust do not have any trials open to recruitment for breast cancer.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours faithfully

Freedom of Information Department
esh-tr.foi@nhs.net